Matinas Biopharma Holdings Inc Dossier
Qualitative Analysis
Business overview
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic products utilizing its proprietary lipid nanocrystal (LNC) platform delivery technology. The LNC platform is designed to enable the oral delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides that are otherwise unstable, poorly bioavailable, or highly toxic when administered intravenously. The company's lead clinical candidate is MAT2203, an oral formulation of the broad-spectrum antifungal agent amphotericin B. MAT2203 is designed to provide targeted, fungicidal delivery with a significantly reduced risk of nephrotoxicity compared to standard intravenous formulations.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the termination of global licensing negotiations for MAT2203 in October 2024, the company pivoted from internal R&D to actively seeking partners to monetize MAT2203 and its lipid nanocrystal (LNC) platform.
Expected impact: Aims to secure non-dilutive funding and licensing revenue to advance MAT2203 into Phase 3 development without further diluting shareholders.
Implemented an immediate 80% workforce reduction (eliminating 15 positions, including three senior management members) and paused internal development of early-stage pipeline programs in oncology and inflammatory diseases.
Expected impact: Significantly lowered operating expenses and extended the remaining cash runway to facilitate strategic evaluations.
Following the $6.0 million investment transaction with David E. Lazar, the company is actively evaluating strategic options to pursue an investment in or acquisition of an operating business (Target Company).
Expected impact: Expected to combine Matinas with an operating business to establish a new path for future growth and stockholder value.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High. Matinas entered into a definitive stock purchase agreement to sell its subsidiary Matinas BioPharma Nanotechnologies, Inc. (including MAT2203 and the LNC platform) to Azurity Pharmaceuticals for $4.0 million upfront, up to $17.5 million in milestones, and mid-single-digit royalties. This transaction successfully monetizes the company's clinical assets.
Terms: $4.0 million in upfront cash consideration, plus up to an additional $17.5 million in potential milestone payments and future mid-single-digit royalties on net sales of MAT2203.